PT - JOURNAL ARTICLE AU - Qin, Na AU - Chen, Congcong AU - Yang, Liu AU - Liu, Su AU - Xie, Yuan AU - Xu, Xianfeng AU - Zhou, Jun AU - Dai, Juncheng AU - Jin, Guangfu AU - Ma, Hongxia AU - Wang, Cheng AU - Shen, Hongbing AU - Hu, Zhibin TI - Interplay between mosaic chromosomal alterations and polygenic risk score increases risk of non-small cell lung cancer AID - 10.1101/2022.04.13.22273440 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.13.22273440 4099 - http://medrxiv.org/content/early/2022/04/18/2022.04.13.22273440.short 4100 - http://medrxiv.org/content/early/2022/04/18/2022.04.13.22273440.full AB - We investigated autosomal mosaic chromosomal alterations (mCAs) in 10,248 non-small cell lung cancer (NSCLC) cases and 9,298 cancer-free controls of Chinese ancestry. Mosaic loss and copy-neutral loss of heterozygosity were associated with an increased risk of NSCLC, while mosaic gain was associated with a decreased risk of NSCLC, especially those spanning telomeres. The increased cell fraction of mCAs was also correlated with an increasing NSCLC risk in the affected individuals. Both multiplicative and additive interactions were observed between polygenic risk score (PRS) and the presence of mosaic loss, where carriers of mosaic loss events with cell fractions ≥5% among the high genetic risk group had the greatest risk for developing NSCLC. These findings suggest that mCA events may act as a new endogenous indicator for risk of NSCLC and have the potential to be jointly used with PRS to optimize risk stratification of NSCLC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors would like to thank all the research staffs and students who participated in this work. This work was supported by the National Natural Science of China (81820108028, 81521004, 81922061, 82103926, 82072579), Research Unit of Prospective Cohort of Cardiovascular Diseases and Cancer, Chinese Academy of Medical Sciences (2019RU038), Natural Science Foundation of Jiangsu Province (BK20210534), and Postdoctoral Science Foundation of China (2021M691636).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Nanjing Medical University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the detected mosaic chromosomal alteration events and genotypic information for the 19 SNPs used for the calculation of polygenic risk score will be included as Supplemental Data before publication.